First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Benjamin Solomon, Todd M. Bauer et al.|New England Journal of Medicine|2020Cited by 1.1k
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKōichi Goto, Pasi A. Jänne, Toshio Kubo et al.|Journal of Clinical Oncology|2023Cited by 293
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A. Yu, Pasi A. Jänne, Yasushi Goto et al.|Journal of Clinical Oncology|2023Cited by 224
Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinomaKouya Shiraishi, Takashi Kohno, Yukinori Okada et al.|Nature Communications|2016Cited by 58
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and ChemotherapyJoel W. Neal, Thomas Newsom-Davis, Nick Pavlakis et al.|Journal of Clinical Oncology|2024Cited by 57